BayHelix And Elsevier Business Intelligence Announce Winners Of China Pharma Awards During PharmAsia Summit Shanghai SHANGHAI, CHINA -- (Marketwired) -- 10/22/13 -- The BayHelix Group and Elsevier Business Intelligence (EBI) announced today the winners of our 2013 China Pharma Awards, which celebrate innovative research and business models in China. "This year's winners exemplify how biopharma innovation is evolving in China across the value chain, from discovery to alliances to creative commercial models," said Jimmy Zhang, PhD, MBA, chairman of BayHelix. "Innovative models have become essential to the strategy and success of both multinationals and leading domestic pharma companies." The 2013 BayHelix-Elsevier Awards were announced at a ceremony during the PharmAsia Summit Shanghai, October 22, 2013. Awards winners were selected by BayHelix and EBI from a list of nominees submitted by members of the China and global pharmaceutical community. "The awards celebrate the contribution of innovative leaders in China as the global industry increasingly recognizes the strategic importance of China and looks for new models for growth," said Joshua Berlin, head of emerging markets for EBI. The 2013 BayHelix-Elsevier Award winners are: R&D Achievement of the Year recognizes a scientific discovery in China with direct impact to drug R&D or a significant achievement in pharmaceutical development milestones. Shenogen Pharma Group, for the discovery of ER-36 as a novel cancer target and development of clinical candidate for breast cancer and liver cancer. Alliance of the Year recognizes a ground breaking pharmaceutical collaboration agreement involving a Chinese entity. BeiGene Ltd./Merck KGaA, for a global licensing, co-development and commercialization agreement for BeiGene-283, a second-generation BRAF inhibitor for the treatment of cancer. Commercial Achievement of the Year recognizes a creative model that delivered superior value to patients/payers in China and commercial success. Novartis AG, for Jian Kang Kuai Che (JKKC), or "Health Express," a social ventures initiative in the Xinjiang region of China. The fourth PharmAsia Summit, organized by EBI and BayHelix, was held October 21-23 in Shanghai. The Summit focused on new R&D and commercial models in a rapidly changing China. During the Summit, top industry leaders from China and the West discussed new growth models for China via a series of case studies, panels and keynotes. For further information, please visit: http://www.PharmAsiaSummit.com. About Elsevier Business Intelligence: Elsevier Business Intelligence, a global leader in the field of healthcare industry information, provides business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, e-learning, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. Our leading publications include PharmAsia News, IN VIVO and "The Pink Sheet." For more information, visit: http://www.ElsevierBi.com. About BayHelix Group: BayHelix is an organization of leaders of Chinese heritage in the global life sciences and healthcare community. We aspire to shape the growth of the life sciences and healthcare industry around the Pacific Rim and beyond, foster and create business opportunities, supply and nurture the leaders for the community, and network and share information and experience. BayHelix is a non-profit organization and its membership is by-invitation-only. For more information, visit: http://www.bayhelix.org. Contact Information Media contact: Kim Gordon Elsevier Business Intelligence +1-908-758-1188 email@example.com
BayHelix And Elsevier Business Intelligence Announce Winners Of China Pharma Awards During PharmAsia Summit Shanghai
Press spacebar to pause and continue. Press esc to stop.